ADVM
Price
$2.28
Change
+$0.02 (+0.88%)
Updated
Jul 3 closing price
Capitalization
47.63M
XENE
Price
$33.26
Change
-$0.11 (-0.33%)
Updated
Jul 3 closing price
Capitalization
2.55B
34 days until earnings call
Interact to see
Advertisement

ADVM vs XENE

Header iconADVM vs XENE Comparison
Open Charts ADVM vs XENEBanner chart's image
Adverum Biotechnologies
Price$2.28
Change+$0.02 (+0.88%)
Volume$73.59K
Capitalization47.63M
Xenon Pharmaceuticals
Price$33.26
Change-$0.11 (-0.33%)
Volume$492.45K
Capitalization2.55B
ADVM vs XENE Comparison Chart in %
Loading...
ADVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADVM vs. XENE commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADVM is a Hold and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (ADVM: $2.28 vs. XENE: $33.26)
Brand notoriety: ADVM and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADVM: 18% vs. XENE: 36%
Market capitalization -- ADVM: $47.63M vs. XENE: $2.55B
ADVM [@Biotechnology] is valued at $47.63M. XENE’s [@Biotechnology] market capitalization is $2.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADVM’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • ADVM’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than ADVM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADVM’s TA Score shows that 3 TA indicator(s) are bullish while XENE’s TA Score has 6 bullish TA indicator(s).

  • ADVM’s TA Score: 3 bullish, 5 bearish.
  • XENE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, XENE is a better buy in the short-term than ADVM.

Price Growth

ADVM (@Biotechnology) experienced а -8.43% price change this week, while XENE (@Biotechnology) price change was +3.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ADVM is expected to report earnings on Apr 15, 2025.

XENE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.55B) has a higher market cap than ADVM($47.6M). XENE YTD gains are higher at: -15.153 vs. ADVM (-51.178). ADVM has higher annual earnings (EBITDA): -154.84M vs. XENE (-290.36M). XENE has more cash in the bank: 550M vs. ADVM (83.1M). XENE has less debt than ADVM: XENE (8.68M) vs ADVM (93.2M). XENE has higher revenues than ADVM: XENE (7.5M) vs ADVM (1M).
ADVMXENEADVM / XENE
Capitalization47.6M2.55B2%
EBITDA-154.84M-290.36M53%
Gain YTD-51.178-15.153338%
P/E RatioN/AN/A-
Revenue1M7.5M13%
Total Cash83.1M550M15%
Total Debt93.2M8.68M1,074%
FUNDAMENTALS RATINGS
ADVM vs XENE: Fundamental Ratings
ADVM
XENE
OUTLOOK RATING
1..100
5827
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
9255
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADVM's Valuation (36) in the Biotechnology industry is somewhat better than the same rating for XENE (76). This means that ADVM’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (42) in the Biotechnology industry is somewhat better than the same rating for ADVM (100). This means that XENE’s stock grew somewhat faster than ADVM’s over the last 12 months.

XENE's SMR Rating (95) in the Biotechnology industry is in the same range as ADVM (99). This means that XENE’s stock grew similarly to ADVM’s over the last 12 months.

XENE's Price Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for ADVM (92). This means that XENE’s stock grew somewhat faster than ADVM’s over the last 12 months.

XENE's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for ADVM (100). This means that XENE’s stock grew significantly faster than ADVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADVMXENE
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 8 days ago
72%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 18 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ADVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLUR5.780.39
+7.26%
Pluri
ATRC31.760.37
+1.18%
AtriCure
HRB56.120.22
+0.39%
H&R Block
JNJ156.010.45
+0.29%
Johnson & Johnson
NKTR24.76-0.77
-3.02%
Nektar Therapeutics

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with IDYA. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
-0.33%
IDYA - XENE
55%
Loosely correlated
+0.82%
CRNX - XENE
54%
Loosely correlated
+1.22%
ATXS - XENE
54%
Loosely correlated
+1.40%
NRIX - XENE
51%
Loosely correlated
+2.33%
KYMR - XENE
50%
Loosely correlated
+0.58%
More